Advances in the management of Ph-positive ALL

Clinical Advances in Hematology and Oncology

Volumn 4, Issue 11, 2006, Pages 804-805

  Hoelzer, Dieter ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DASATINIB; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESPONSE; ELDERLY CARE; GENE MUTATION; GERIATRIC PATIENT; HUMAN; MONOTHERAPY; PHARMACOGENETICS; PHILADELPHIA CHROMOSOME POSITIVE CELL; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

AGING; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; MALE; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 33845370792     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Jabbour E, Cortes J, Kantarjian HM, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after BCR-ABL kinase mutation-related imatinib failure. Blood. 2006;108:1421-1423.
2. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103:4396-4407.
3. Hoelzer D, Goekbuget N, Ottmann OG. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Semin Hematol. 2002;39(4 suppl 3):32-37.
4. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood. 2006;108:1469-1477.